Incidence and grade of CRS by dose and cycle among group I patients who received RO7283420 IV
| n (%) . | Cycle 1, day 1 1 mg (n = 40) . | Cycle 1, day 8 3 mg∗ (n = 28) . | Cycle 1, day 15 6-18 mg† (n = 22) . | Cycle 2, day 1 6-18 mg† (n = 6) . | Cycle 3 to EOT 6-18 mg† (n = 10) . |
|---|---|---|---|---|---|
| All grades | 20 (50) | 8 (28.6) | 8 (36.4) | 2 (33.3) | 5 (50) |
| Grade 1 | 11 (27.5) | 6 (21.4) | 7 (31.8) | 2 (33.3) | 4 (40) |
| Grade 2 | 8 (20) | 1 (3.6) | 1 (4.5) | 0 | 0 |
| Grade 3 | 1 (2.5) | 1 (3.6) | 0 | 0 | 1 (10) |
| n (%) . | Cycle 1, day 1 1 mg (n = 40) . | Cycle 1, day 8 3 mg∗ (n = 28) . | Cycle 1, day 15 6-18 mg† (n = 22) . | Cycle 2, day 1 6-18 mg† (n = 6) . | Cycle 3 to EOT 6-18 mg† (n = 10) . |
|---|---|---|---|---|---|
| All grades | 20 (50) | 8 (28.6) | 8 (36.4) | 2 (33.3) | 5 (50) |
| Grade 1 | 11 (27.5) | 6 (21.4) | 7 (31.8) | 2 (33.3) | 4 (40) |
| Grade 2 | 8 (20) | 1 (3.6) | 1 (4.5) | 0 | 0 |
| Grade 3 | 1 (2.5) | 1 (3.6) | 0 | 0 | 1 (10) |